These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

195 related items for PubMed ID: 8740329

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Nipple vasospasms, Raynaud's syndrome, and nifedipine.
    Garrison CP.
    J Hum Lact; 2002 Nov; 18(4):382-5. PubMed ID: 12449056
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. [Controlled study of nifedipine in the treatment of Raynaud's phenomenon].
    Kahan A, Weber S, Amor B, Saporta L, Hodara M, Degeorges M.
    Rev Rhum Mal Osteoartic; 1982 Apr; 49(5):337-43. PubMed ID: 6285445
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Vascular response of Raynaud's phenomenon to nifedipine or herbal medication (duhuo-tisheng tang with danggui-sini tang): a preliminary study.
    Wu YJ, Luo SF, Yang SH, Chen JY, Yu KH, See LC.
    Chang Gung Med J; 2008 Apr; 31(5):492-502. PubMed ID: 19097597
    [Abstract] [Full Text] [Related]

  • 28. Anorexia nervosa and Raynaud's phenomenon: a case report.
    Yucel B, Uzum AK, Ozbey N, Kamali S, Yager J.
    Int J Eat Disord; 2007 Dec; 40(8):762-5. PubMed ID: 17607716
    [Abstract] [Full Text] [Related]

  • 29. Effect of the calcium channel blocker nifedipine on Raynaud's phenomenon. A controlled double blind trial.
    Sauza J, Kraus A, González-Amaro R, Alarcón-Segovia D.
    J Rheumatol; 1984 Jun; 11(3):362-4. PubMed ID: 6376801
    [Abstract] [Full Text] [Related]

  • 30. Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud's phenomenon. A randomized, controlled study.
    Scorza R, Caronni M, Mascagni B, Berruti V, Bazzi S, Micallef E, Arpaia G, Sardina M, Origgi L, Vanoli M.
    Clin Exp Rheumatol; 2001 Jun; 19(5):503-8. PubMed ID: 11579708
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Laser-Doppler flowmetry in the assessment of "mild" Raynaud's phenomenon and its treatment.
    Cesarone MR, Laurora G, Smith SR, Belcaro G.
    Panminerva Med; 1990 Jun; 32(4):151-4. PubMed ID: 2090987
    [Abstract] [Full Text] [Related]

  • 35. [Cyanotic Raynaud's phenomenon: a peculiar symptomatologic entity].
    Andreozzi GM, Signorelli S, Monaco S, Martini R, Ferrara M, Palazzo V.
    J Mal Vasc; 1988 Jun; 13(2):179. PubMed ID: 3397677
    [No Abstract] [Full Text] [Related]

  • 36. Raynaud's phenomenon and nifedipine.
    Kraus A.
    J Rheumatol; 1989 Jul; 16(7):1013. PubMed ID: 2597264
    [No Abstract] [Full Text] [Related]

  • 37. Clinical features and management of erythromelalgia: long term follow-up of 46 cases.
    Parker LK, Ponte C, Howell KJ, Ong VH, Denton CP, Schreiber BE.
    Clin Exp Rheumatol; 2017 Jul; 35(1):80-84. PubMed ID: 27494156
    [Abstract] [Full Text] [Related]

  • 38. Triiodothyronine treatment for Raynaud's phenomenon: a controlled trial.
    Dessein PH, Morrison RC, Lamparelli RD, van der Merwe CA.
    J Rheumatol; 1990 Aug; 17(8):1025-8. PubMed ID: 2213778
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.